- In January 2025, Pfizer announced the launch of its new combination oral NSAID, Aptisolve, in the European Union, following approval from the European Medicines Agency (EMA). Aptisolve is a novel formulation designed to provide enhanced pain relief for patients suffering from osteoarthritis and rheumatoid arthritis
- In October 2024, Johnson & Johnson unveiled a new extended-release formulation of Ibuprofen XR at the American College of Rheumatology (ACR) Annual Meeting. This new formulation provides patients with longer-lasting pain relief, reducing the need for frequent dosing, and improving adherence. The drug is primarily aimed at patients with chronic conditions such as osteoarthritis and ankylosing spondylitis, with a focus on reducing gastrointestinal side effects commonly associated with traditional NSAIDs
- In September 2024, Bayer Pharmaceuticals launched its Nexaflex oral NSAID for the treatment of acute pain associated with sports injuries and muscle strains. The product was introduced in North America and is marketed as a safer, more effective alternative to traditional NSAIDs. Nexaflex is designed to provide rapid pain relief while minimizing the risk of gastrointestinal irritation, making it an ideal option for athletes and active individuals
- In September 2024, GlaxoSmithKline (GSK) announced the acquisition of a new NSAID technology from a biopharmaceutical startup that enhances the effectiveness of ibuprofen while reducing adverse effects on the gastrointestinal system
- In May-2022, Dr. Reddy's Laboratories released Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market. This product is a nonsteroidal anti-inflammatory drug (NSAID) recommended for the short-term management of moderately serious acute pain, that offers analgesia at the opioid stage and used only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if necessary
